US Supreme Court could rethink induced infringement with ‘skinny label’ case
The US Supreme Court is set to hear oral arguments in Hikma Pharmaceuticals v. Amarin Pharma next week over what constitutes induced patent infringement for generic medications sold with a so-called...To view the full article, register now.
Already a subscriber? Click here to view full article